Identification and Treatment of Prediabetes to Prevent Progression to Type 2 Diabetes

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) American Diabetes Association, 2003, Economic costs of diabetes in the U.S. in 2002, Diabetes Care, 26, 917, 10.2337/diacare.26.3.917 UK Prospective Diabetes Study Group, 1995, UK Prospective Diabetes Study 16. Overview of 6 years' therapy of type II diabetes: A progressive disease [published correction appears in Diabetes. 1996;45:1655], Diabetes, 44, 1249, 10.2337/diabetes.44.11.1249 Icks, 2007, Clinical and cost-effectiveness of primary prevention of type 2 diabetes in a ‘real world’ routine healthcare setting: Model based on the KORA Survey 2000, Diabet Med, 24, 473, 10.1111/j.1464-5491.2007.02108.x Jacobs-van der Bruggen, 2007, Lifestyle interventions are cost-effective in people with different levels of diabetes risk. Results from a modeling study, Diabetes Care, 30, 128, 10.2337/dc06-0690 American Diabetes Association, 2007, Standards of medical care in diabetes—2007, Diabetes Care, 30, S4, 10.2337/dc07-S004 Biuso, 2007, A conceptual framework for targeting prediabetes with lifestyle, clinical, and behavioral management interventions, Disease Management, 10, 6, 10.1089/dis.2006.628 Pan, 1997, Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerances. The Da Qing IGT and Diabetes Study, Diabetes Care, 20, 537, 10.2337/diacare.20.4.537 Diabetes Prevention Program Research Group, 2002, Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin, N Engl J Med, 346, 393, 10.1056/NEJMoa012512 Lindstrom, 2003, Prevention of diabetes mellitus in subjects with impaired glucose tolerance in the Finnish Diabetes Prevention Study: Results from a randomized clinical trial, J Am Soc Nephrol, 14, S108, 10.1097/01.ASN.0000070157.96264.13 Buchanan, 2002, Preservation of pancreatic β-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women, Diabetes, 51, 2796, 10.2337/diabetes.51.9.2796 DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators, 2006, Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: A randomised controlled trial, Lancet, 368, 1096, 10.1016/S0140-6736(06)69420-8 DREAM Trial Investigators, 2006, Effect of ramipril on the incidence of diabetes, N Engl J Med, 355, 1551, 10.1056/NEJMoa065061 Chiasson, 2003, Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance. The STOP-NIDDM trial, JAMA, 290, 486, 10.1001/jama.290.4.486 Pan, 2003, Efficacy of acarbose in Chinese subjects with impaired glucose tolerance, Diabetes Res Clin Pract, 61, 183, 10.1016/S0168-8227(03)00117-7 Torgerson, 2004, XENical in the prevention of Diabetes in Obese Subjects (XENDOS) study, Diabetes Care, 27, 155, 10.2337/diacare.27.1.155 Walker, 2006, Adherence to preventive medications: Predictors and outcomes in the Diabetes Prevention Program, Diabetes Care, 29, 1997, 10.2337/dc06-0454 Ratner, 2006, An update on the Diabetes Prevention Program, Endocr Pract, 12, 20, 10.4158/EP.12.S1.20 Xiang, 2006, Effect of pioglitazone on pancreatic β-cell function and diabetes risk in Hispanic women with prior gestational diabetes, Diabetes, 55, 517, 10.2337/diabetes.55.02.06.db05-1066 Parulkar, 2001, Nonhypoglycemic effects of thiazolidinediones, Ann Intern Med, 134, 61, 10.7326/0003-4819-134-1-200101020-00014 Nissen, 2007, Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes, N Engl J Med, 356, 1304, 10.1056/NEJMoa070635 Hamman, 2006, Effect of weight loss with lifestyle intervention on risk of diabetes, Diabetes Care, 29, 2102, 10.2337/dc06-0560 UK Prospective Diabetes Study (UKPDS) Group, 1998, Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33), Lancet, 352, 837, 10.1016/S0140-6736(98)07019-6 UK Prospective Diabetes Study (UKPDS) Group, 1998, Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34), Lancet, 352, 854, 10.1016/S0140-6736(98)07037-8 Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group, 2002, Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus, JAMA, 287, 2563, 10.1001/jama.287.19.2563 Nathan, 2006, Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes, Diabetes Care, 29, 1963, 10.2337/dc06-9912 Weber, 2006, Hypertension treatment and implications of recent cardiovascular outcome trials, J Hypertens, 24, S37, 10.1097/01.hjh.0000220102.35025.eb